Publications by authors named "G V Trunova"

Article Synopsis
  • - COVID-19 is a serious and contagious respiratory illness, leading to the search for new treatments, particularly looking into polysaccharides with antiviral potential.
  • - The study focused on the antiviral effects of the drug "Immeran" against SARS-CoV-2 in hamsters, testing doses of 500 and 1000 μg/kg through intraperitoneal injections.
  • - Results showed that Immeran effectively reduced virus replication in the lungs and, at the higher dose, prevented weight loss in hamsters, while also promoting the production of anti-SARS-CoV-2 antibodies, indicating it might enhance immune responses.
View Article and Find Full Text PDF

Destroying tumor vasculature is a relevant therapeutic strategy due to its involvement in tumor progression. However, adaptive resistance to approved antiangiogenic drugs targeting VEGF/VEGFR pathway requires the recruitment of additional targets. In this aspect, targeting TRAIL pathway is promising as it is an important component of the immune system involved in tumor immunosurveillance.

View Article and Find Full Text PDF

As novel SARS-CoV-2 Variants of Concern emerge, the efficacy of existing vaccines against COVID-19 is declining. A possible solution to this problem lies in the development of a live attenuated vaccine potentially able of providing cross-protective activity against a wide range of SARS-CoV-2 antigenic variants. Cold-adapted (ca) SARS-CoV-2 variants, Dubrovka-ca-B4 (D-B4) and Dubrovka-ca-D2 (D-D2), were obtained after long-term passaging of the Dubrovka (D) strain in Vero cells at reduced temperatures.

View Article and Find Full Text PDF

Introduction: The variability of SARS-CoV-2 appeared to be higher than expected, the emergence of new variants raises concerns. The aim of the work was to compare the pathogenicity of the Wuhan and BA.1.

View Article and Find Full Text PDF

One of the most important steps in the development of drugs and vaccines against a new coronavirus infection is their testing on a relevant animal model. The laboratory mouse, with well-studied immunology, is the preferred mammalian model in experimental medicine. However, mice are not susceptible to infection with SARS-CoV-2 due to the lack of human angiotensin-converting enzyme (hACE2), which is the cell receptor of SARS-CoV-2 and necessary for the entry of the virus into the cell.

View Article and Find Full Text PDF